11 investors are actively funding Oxford biotech companies in 2026. Oxford Science Enterprises backed Beacon Therapeutics' $75M+ Series C in January 2026. OrganOx was acquired for $1.5B in August 2025. UK biotech raised £552M in Q1 2026 alone.
Oxford is the UK's second largest biotech hub after London. The Golden Triangle connects Oxford, Cambridge, and London into one interconnected capital network for life science founders.
University of Oxford spinouts raised more than any other UK university in 2025. OrganOx and Oxford Ionics both exited for over $1B. That track record attracts capital from across Europe and the US.
Oxford biotech investors move slower than software VCs. Clinical data requirements, regulatory milestones, and IP licensing negotiations add 30-90 days to standard due diligence timelines.
Set up an Ellty data room with your preclinical data, IP assignments, and cap table before any first meeting. Oxford biotech investors ask for technical documentation within 48 hours.
| Type | Check size | Sector focus | Website | |
|---|---|---|---|---|
| Oxford Science Enterprises | University VC | Seed to Series C+ | Life sciences, health tech, deep tech | oxfordscienceenterprises.com |
| Syncona | Listed life science investor | Series A to growth | Gene therapy, cell therapy, rare disease | synconaltd.com |
| Advent Life Sciences | European biotech VC | Series A to B | Therapeutics, rare disease, gene therapy | adventls.com |
| Forbion | European life science VC | Seed to Series B | Biopharmaceuticals, gene therapy, rare disease | forbion.com |
| Parkwalk Advisors | University spinout VC | Pre-seed to Series A | Oxford spinouts, life sciences, EIS | parkwalk.vc |
| Novo Holdings | Global life science investor | Seed to growth | Biopharma, diagnostics, health tech | novoholdings.dk |
| Longwall Ventures | Oxford early-stage VC | Seed to Series A | Oxford spinouts, life sciences, deep tech | longwall.vc |
| Oxford Capital | EIS/SEIS fund | Seed to Series A | Oxford-area life sciences, deep tech | oxcp.com |
| SV Health Investors | Global health VC | Series A to C | Biotech, medtech, dementia, rare disease | svhealthinvestors.com |
| Oxford Technology Management | Oxford-area early-stage VC | Seed to Series A | Oxford tech and life sciences | oxfordtechnology.com |
| BGF | Growth equity | £3M-£30M | Life sciences scale-ups, medtech | bgf.co.uk |
Track who opens your Oxford biotech data room
Build an Ellty data room. See which investors open your preclinical data.
Start free 14-day trialWhat is an Oxford biotech investor?
Oxford biotech investors back life science companies built on University of Oxford research or located in the Oxford-Reading-Chilterns corridor. They differ from generalist VCs by focusing on clinical milestones and IP licensing as primary investment triggers.
Most Oxford biotech VCs co-invest together. OSE, Syncona, Forbion, and Advent Life Sciences all participated in Beacon Therapeutics' $75M+ Series C in January 2026. Syndicated rounds are the norm, not the exception.
Check sizes range from £150K at Oxford Capital's EIS fund to multi-hundred-million-dollar growth rounds from Novo Holdings. Longwall Ventures and Oxford Technology Management cover the earliest-stage Oxford spinouts.
Read how Oxford AI investors approach technical due diligence differently. Several Oxford biotech investors also back AI-enabled drug discovery platforms alongside wet-lab companies.
Oxford has produced more billion-dollar biotech exits than any other UK university. The quality of science coming out of the Radcliffe Department, the Jenner Institute, and the Target Discovery Institute is unmatched in Europe.
11 Oxford biotech investors
1. Oxford Science Enterprises
Oxford Science Enterprises is a £1.1B investment company and the largest university spinout fund in Europe outside the US. They backed Beacon Therapeutics' $75M+ Series C in January 2026 alongside Goldman Sachs and Syncona. In 2025 they backed Scripta Therapeutics (€10M+), Valink Therapeutics ($11.8M), and Wild Bioscience (€51M). OSE raised £175M in venture debt via Goldman Sachs and Deutsche Bank in April 2025.
Set up an Ellty data room with your preclinical data, IP assignments, and cap table before approaching OSE. Their team of 16 partners runs detailed technical reviews within 48 hours of first contact.
- Recent Deals: Beacon Therapeutics $75M+ Series C (January 2026); Allos Global (2026); Wild Bioscience €51M (2025); Scripta Therapeutics €10M+ (2025); £175M venture debt raised (April 2025)
- LinkedIn: Oxford Science Enterprises LinkedIn
- Sector Focus: Life sciences, health tech, AI, deep tech
- Stage Focus: Seed to Series C+
- Location: Oxford, UK
- Website: oxfordscienceenterprises.com
2. Syncona
Syncona is a London-listed life science investor with a £765M portfolio across 14 companies. They committed $24.5M to Beacon Therapeutics' $75M Series C in December 2025. Syncona backs Oxford University spinouts including OMass Therapeutics and Beacon Therapeutics. Their portfolio is 78.5% concentrated in clinical-stage and commercial companies.
- Recent Deals: Beacon Therapeutics $75M+ Series C (December 2025/January 2026); OMass Therapeutics portfolio; $24.5M committed to Beacon; 14 portfolio companies
- LinkedIn: Syncona LinkedIn
- Sector Focus: Gene therapy, cell therapy, rare disease, Oxford spinouts
- Stage Focus: Series A to growth
- Location: London with Oxford deal flow
- Website: synconaltd.com
3. Advent Life Sciences
Advent Life Sciences is a European biotech VC that backed Beacon Therapeutics' oversubscribed $75M+ Series C in January 2026. They focus on clinical-stage therapeutics companies across Europe with particular strength in rare disease and gene therapy. Advent is a regular co-investor with OSE and Forbion on Oxford biotech rounds.
- Recent Deals: Beacon Therapeutics $75M+ Series C participant (January 2026); rare disease and gene therapy portfolio; European biotech focus
- LinkedIn: Advent Life Sciences LinkedIn
- Sector Focus: Therapeutics, rare disease, gene therapy
- Stage Focus: Series A to B
- Location: London and Switzerland
- Website: adventls.com
4. Forbion
Forbion is a European life science VC that backed Beacon Therapeutics' $75M+ Series C in January 2026 alongside OSE and Syncona. They manage €2B+ across multiple funds focused on biopharmaceuticals, gene therapy, and rare diseases. Forbion is one of the most active European investors in Oxford biotech alongside Advent Life Sciences.
- Recent Deals: Beacon Therapeutics $75M+ Series C participant (January 2026); €2B+ AUM; European biopharmaceutical and gene therapy portfolio
- LinkedIn: Forbion LinkedIn
- Sector Focus: Biopharmaceuticals, gene therapy, rare disease
- Stage Focus: Seed to Series B
- Location: Netherlands with Oxford deal flow
- Website: forbion.com
5. Parkwalk Advisors
Parkwalk Advisors manages £450M+ and is the most active EIS fund backing UK university spinouts. They back Oxford biotech pre-seed to Series A founders with university IP. Parkwalk co-invests with OSE and Longwall Ventures on Oxford spinout seed rounds. Their Oxford portfolio spans life sciences, deep tech, and health tech.
- Recent Deals: AccelerComm $15M lead (June 2025); 41 spinout deals in 2024; £450M+ AUM; Oxford and Cambridge focus
- LinkedIn: Parkwalk Advisors LinkedIn
- Sector Focus: Oxford spinouts, life sciences, EIS
- Stage Focus: Pre-seed to Series A
- Location: London with Oxford focus
- Website: parkwalk.vc
Share your Oxford biotech pitch with trackable links
Use Ellty to see which investors open your clinical data and IP documents.
Start free 14-day trial6. Novo Holdings
Novo Holdings is a €93B global life science investor wholly owned by the Novo Nordisk Foundation. They invested £50M in Oxford Nanopore Technologies and intend to increase their stake over time. Novo Holdings backs Oxford biotech companies across venture, growth, and listed stages. They are one of the most important long-term capital providers in the Oxford life science ecosystem.
- Recent Deals: Oxford Nanopore Technologies £50M stake; €93B AUM; global life science venture to growth mandate
- LinkedIn: Novo Holdings LinkedIn
- Sector Focus: Biopharma, diagnostics, health tech, life sciences
- Stage Focus: Seed to listed
- Location: Copenhagen with UK deal flow
- Website: novoholdings.dk
7. Longwall Ventures
Longwall Ventures backs early-stage Oxford spinouts in life sciences and deep tech alongside OSE and Oxford Technology Management. They co-invested in Caristo's £16.3M Series A alongside OSE and BGF. Longwall participated in the June 2026 Oxford Venture Tour as a lead early-stage Oxford investor. They are the most active seed-stage co-investor in the OSE network.
Upload your Oxford biotech pitch to Ellty before approaching Longwall. Early-stage Oxford investors respond faster to founders with organised, trackable document packs.
- Recent Deals: Caristo £16.3M Series A (with OSE and BGF); June 2026 Oxford Venture Tour participant; Oxford spinout seed mandate
- LinkedIn: Longwall Ventures LinkedIn
- Sector Focus: Oxford spinouts, life sciences, deep tech
- Stage Focus: Seed to Series A
- Location: Oxford, UK
- Website: longwall.vc
8. Oxford Capital
Oxford Capital manages EIS and SEIS funds focused on Oxford-area technology and life science companies. They invested £4M in NavLive (University of Oxford spinout) in May 2025. Oxford Capital is the primary EIS fund for Oxford founders who want angel-scale capital with a local institutional backer. They co-invest with OSE and Longwall Ventures on seed-stage rounds.
Read about virtual data rooms for biotech before approaching Oxford Capital. EIS fund investors run document-intensive due diligence even at seed stage.
- Recent Deals: NavLive £4M Series A (May 2025); Oxford-area EIS/SEIS fund active 2025-2026; Oxford University spinout focus
- LinkedIn: Oxford Capital LinkedIn
- Sector Focus: Oxford-area life sciences, deep tech, EIS
- Stage Focus: Seed to Series A
- Location: Oxford, UK
- Website: oxcp.com
9. SV Health Investors
SV Health Investors is a global health VC with 50+ investment professionals based in Boston and London. They back biotech, medtech, and healthcare growth equity across Europe and the US. SV Health focuses on dementia, rare disease, and next-generation therapeutics where Oxford has particular research strength. Oxford founders raising Series A and B should include SV Health in their investor list.
- Recent Deals: Active European biotech Series A and B mandate; dementia and rare disease focus; London and Boston operations; 50+ investment team
- LinkedIn: SV Health Investors LinkedIn
- Sector Focus: Biotech, medtech, dementia, rare disease
- Stage Focus: Series A to C
- Location: London and Boston
- Website: svhealthinvestors.com
10. Oxford Technology Management
Oxford Technology Management is an Oxford-based early-stage investor focused on science and technology spinouts from the University of Oxford. They participated in the June 2026 Oxford Venture Tour alongside OSE, Longwall Ventures, and Oxford University Innovation. They back Oxford biotech founders at the earliest stages before OSE and Parkwalk can lead.
- Recent Deals: June 2026 Oxford Venture Tour participant; Oxford University Innovation co-investor; early-stage Oxford science and tech mandate
- LinkedIn: Oxford Technology Management LinkedIn
- Sector Focus: Oxford tech and life sciences, early-stage spinouts
- Stage Focus: Seed to Series A
- Location: Oxford, UK
- Website: oxfordtechnology.com
11. BGF
BGF is the most active growth equity investor in the UK and Ireland. They co-invested in Caristo's £16.3M Series A alongside OSE and Longwall Ventures. BGF backs Oxford life science companies past seed with £3M to £30M growth equity checks. Oxford biotech founders with early clinical traction seeking their first institutional growth round should approach BGF alongside SV Health.
- Recent Deals: Caristo £16.3M Series A (with OSE and Longwall); most active UK equity investor; Oxford life science growth mandate
- LinkedIn: BGF LinkedIn
- Sector Focus: Life sciences scale-ups, medtech, Oxford-area
- Stage Focus: Series A and beyond
- Location: UK-wide with Oxford coverage
- Website: bgf.co.uk
What to research before reaching out to Oxford biotech VCs
Know which University of Oxford department your science comes from. OSE, Longwall, and Parkwalk evaluate Oxford spinouts partly by the quality of the originating lab. Weak IP provenance from a lesser-known department is harder to sell.
Check which investors are already in your competitive space. If OSE backed a similar platform, they won't back yours. Forbion and Advent Life Sciences both have anti-portfolio overlap policies. Research their portfolios before any first contact.
Identify your lead investor before approaching the syndicate. Oxford biotech rounds are co-invested, but someone has to lead. OSE or Syncona typically lead. Don't approach Advent, Forbion, or Novo Holdings as a lead without a co-lead commitment already secured.
Use Ellty to share your competitive landscape analysis and preclinical data package with investors. Track who spends time on your mechanism of action data - those are the investors to follow up first.
How to prepare clinical data for Oxford biotech investors
Oxford biotech investors expect preclinical proof of concept before seed. Animal model data, target validation, and at least one peer-reviewed publication are baseline for OSE and Syncona.
Phase 1 data is what unlocks Series A from Advent Life Sciences, Forbion, and Syncona. You don't need efficacy results - safety and tolerability data with a credible PK/PD profile is enough to start the conversation.
Don't present interim data without context. Oxford biotech investors will ask who reviewed your statistical analysis and whether your endpoints are FDA or EMA-aligned. Prepare for those questions before any first meeting.
How to verify an Oxford biotech fund is still deploying
Check the fund's portfolio page for investments closed in the last 12 months. OSE backed two companies in the first six weeks of 2026. Syncona is in portfolio realisation mode as of mid-2025 and is unlikely to lead new deals.
Longwall Ventures, Parkwalk, and Oxford Capital are all confirmed active in 2026. Forbion closed a new fund in 2024 and is actively deploying across European biotech companies.
Read the due diligence checklist for investors before approaching multiple Oxford biotech VCs simultaneously. Managing parallel processes with 4+ investors requires disciplined pipeline tracking.
How to pitch an Oxford biotech investor
Four steps that match how life science VCs evaluate Oxford spinouts before writing a check.
- 1.Resolve your University of Oxford IP licence firstOSE and Parkwalk check IP assignments before any term sheet.
- 2.Prepare preclinical proof-of-concept data upfrontSyncona and OSE require animal model data before seed meetings.
- 3.Identify a lead investor before approaching the syndicateOSE or Syncona lead most rounds. Confirm the lead before others.
- 4.Set up your data room before reaching out to any investorOxford biotech VCs request documents within 48 hours of first contact.
How Ellty helps you land an Oxford biotech investor
Oxford biotech VCs move fast once interested. Organise your clinical and IP documents before first contact.
- 1.Build a biotech data room with clinical documentsUpload trial data, IP licences, and cap table securely.
- 2.Set permissions before sharing with biotech VCsRequire email to view. Protect unpublished trial data.
- 3.Track which investors open your clinical data sectionSee who reviews your MoA slides. Follow up those VCs first.
Questions from Oxford biotech founders
- Primarily spinouts. But OSE considers Oxford-linked founders with strong science elsewhere.
- At minimum: animal model data and a peer-reviewed publication. Target validation helps.
- OSE leads most Oxford spinout seeds. Longwall and Parkwalk co-invest at the same stage.
- Before first contact. Investors request your IP docs and trial data within 48 hours.
- Typically 60-90 days minimum. IP licensing reviews and clinical data checks add time.
- Approach OSE first. They lead most Oxford Series A rounds and bring Forbion in as co-lead.
